Kobayashi Pharmaceutical Co., Ltd.

Kobayashi Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells consumer products in Japan and internationally. The company provides products in the areas of healthcare, household products, skincare, and body warmers. It also offers Ammeltz, a topical analgesic; Inochi no Haha, a women's health medicine; Sarasaty lingerie soap; Bluelet Decoral, a toilet bowl cleaner and freshener; Naishitol, a Chinese medicine; Eaude Muge, a medicated lotion for preventing acne; Itoyoji, a dental floss pick; BreathCare, an oral breath freshener capsule; Eyebon, an eye wash; Netsusama sheet, a cooling gel sheet for forehead; Sawaday, a toilet air freshener; and deodorizing air freshener, lens cleaner, and oral hygiene products. Additionally, the company manufactures and sells pharmaceuticals, quasi-drugs, cosmetics, hygiene and paper products, health foods, and processed synthetic resin products; markets nutritional supplements and skin care products through website and over the phone; and sells skincare products, daily necessities, and health foods. Further, it engages in transportation, real estate management, and advertising planning and production businesses; and asset management. Kobayashi Pharmaceutical Co., Ltd. was founded in 1886 and is headquartered in Osaka, Japan.

Kobayashi Pharmaceutical Co., Ltd. trades as KBYPF on OTC. The company is classified in Consumer Defensive / Household & Personal Products and reports in USD.

The current profile places the business in Household & Personal Products. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $165.89B of revenue and $3.66B of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Kobayashi Pharmaceutical Co., Ltd. can be compared against peers such as Société BIC S.A., Blue Moon Group Holdings Limited, KWS SAAT SE & Co. KGaA, KOSÉ Corporation, Lion Corporation, Milbon Co., Ltd..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $2.53B, beta of 0.26, and return on equity of +1.7%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

KBYPF currently shows total debt of $678.59M and beta of 0.26. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.kobayashi.co.jp

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.